Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - ARIAD PHARMACEUTICALS INC | a50773305ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 20, 2013
ARIAD Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware
|
0-21696
|
22-3106987
|
|
(State or other jurisdiction
|
(Commission
|
(I.R.S. Employer
|
|
of incorporation)
|
File Number)
|
Identification No.)
|
|
26 Landsdowne Street, Cambridge, Massachusetts
|
02139
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant's telephone number, including area code: (617) 494-0400
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
1
ITEM 8.01 Other Events.
On December 20, 2013, ARIAD Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration has approved a revised U.S. Prescribing Information and a Risk Evaluation and Mitigation Strategy (REMS) for Iclusig® (ponatinib) that allows immediate resumption of its marketing and commercial distribution. The USPI includes a revised indication statement and boxed warning, updated safety information and recommendations regarding dosing considerations for prescribers.
ARIAD management will host a conference call and webcast to discuss these actions today, December 20, at 11:30 a.m. ET.
A copy of the press release is being filed herewith as Exhibit 99.1 and is incorporated by reference herein.
ITEM 9.01 Financial Statements and Exhibits
(d) The following exhibit is filed with this report:
Exhibit
Number Description
|
99.1
|
Press Release dated December 20, 2013.
|
The press release contains hypertext links to information on our websites. The information on our websites is not incorporated by reference into this Current Report on Form 8-K and does not constitute a part of this Form 8-K.
2
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ARIAD Pharmaceuticals, Inc.
|
||
|
By:
|
/s/ Edward M. Fitzgerald
|
|
|
Edward M. Fitzgerald
|
||
|
Executive Vice President, Chief Financial Officer
|
||
Date: December 20, 2013
3